Liu Xiaomei, Li Xiuqin, Qu Hui, Zhang Shiyue, Zhang Ruizhe, Du Zhenhua
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Shanghai Junshi Biosciences Co, Ltd., Shanghai, China.
Front Oncol. 2022 Apr 14;12:815917. doi: 10.3389/fonc.2022.815917. eCollection 2022.
Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in patients who developed chemo-refractory carcinomas, whereas no study has ever investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma. Here we reported the effectiveness and safety data of 4 patients with chemo-resistant choriocarcinoma who underwent PD-1 antibody therapy by toripalimab and individualized chemotherapies. From January 2019 to August 2020, 4 patients with choriocarcinoma were admitted in Shengjing Hospital of China Medical University. The patients' age ranged from 29 to 52 years with a median of 36 years. All the patients achieved CR after the combined therapy of toripalimab with individualized chemotherapies according to the decreased serum β-hcg level. Two of the four patients were observed with treatment-related adverse events (AEs), including one grade I skin rash and one grade I pruritus. Our cases showed that toripalimab combined with chemotherapy presented a tolerable safety profile and promising effectiveness in patients with chemo-resistant choriocarcinoma, indicating its potential as salvage therapy for this subset of patients.
托瑞帕利单抗作为一种新型的PD-1抑制剂，在化疗难治性癌症患者中已显示出有前景的疗效，然而，尚无研究探讨托瑞帕利单抗在化疗耐药性绒毛膜癌中的有效性。在此，我们报告了4例接受托瑞帕利单抗PD-1抗体治疗及个体化化疗的化疗耐药性绒毛膜癌患者的有效性和安全性数据。2019年1月至2020年8月，中国医科大学盛京医院收治了4例绒毛膜癌患者。患者年龄在29岁至52岁之间，中位年龄为36岁。根据血清β-hcg水平下降情况，所有患者在托瑞帕利单抗与个体化化疗联合治疗后均达到完全缓解。4例患者中有2例出现与治疗相关的不良事件（AE），包括1例1级皮疹和1例1级瘙痒。我们的病例表明，托瑞帕利单抗联合化疗在化疗耐药性绒毛膜癌患者中显示出可耐受的安全性和有前景的有效性，表明其作为该亚组患者挽救治疗的潜力。
